Last update 21 Nov 2024
HZ-H08905
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CK1ε inhibitors(casein kinase 1 epsilon inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with HZ-H08905HZ-H08905在复发和/或难治性外周T细胞淋巴瘤患者的有效性和安全性的II期临床研究
[Translation] Phase II clinical study on the efficacy and safety of HZ-H08905 in patients with relapsed and/or refractory peripheral T-cell lymphoma
评价HZ-H08905单药对比西达本胺单药治疗复发/难治外周T细胞淋巴瘤随机、双盲、多中心的III期临床研究
[Translation] A randomized, double-blind, multicenter phase III clinical study evaluating HZ-H08905 monotherapy versus chidamide monotherapy in the treatment of relapsed/refractory peripheral T-cell lymphoma
HZ-H08905在复发或难治性非霍奇金淋巴瘤患者的安全性/耐受性及药代动力学的I期临床研究
[Translation] Phase I clinical study of the safety/tolerability and pharmacokinetics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma
100 Clinical Results associated with HZ-H08905
Login to view more data
100 Translational Medicine associated with HZ-H08905
Login to view more data
100 Patents (Medical) associated with HZ-H08905
Login to view more data
100 Deals associated with HZ-H08905
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Peripheral T-Cell Lymphoma | Phase 3 | CN | 28 Jun 2024 | |
| Non-Hodgkin's lymphoma refractory | Phase 1 | CN | 29 Dec 2021 | |
| Recurrent Non-Hodgkin Lymphoma | Phase 1 | CN | 29 Dec 2021 | |
| B-cell lymphoma recurrent | IND Approval | CN | 15 Dec 2023 | |
| B-cell lymphoma refractory | IND Approval | CN | 15 Dec 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 50 | (olkyajzung) = neutropenia, leukopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, thrombocytopenia, pneumonia, anemia, rash, elevated serum creatinine, sinus bradycardia, hyperuricemia, abnormal liver function, hypertriglyceridemia, diarrhea, and dermatitis medicamentosa lmzhcxptmp (lotfctbunn ) View more | Positive | 08 Dec 2024 | |||
Phase 1 | 24 | zyilewukzo(vmjcmsljln) = TRAEs occurring in ≥10% of patients were neutropenia, leukopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated serum creatinine, thrombocytopenia, elevated blood bilirubin, rash, hypercholesteremia, pneumonia, upper respiratory infection, hyperlipidemia, hypertriglyceridemia, hyperuricemia, anemia, elevated blood lactate dehydrogenase and elevated gamma glutamyl transpeptidase oeqxpkxkds (gnjbdmnony ) View more | Positive | 08 Dec 2024 | |||
Phase 1 | 38 | (sutoctmddb) = cdgorgjbwc slkjaaaceq (wyhopbfmvo ) View more | - | 11 Dec 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free